Dermatology Times 2024 In Review: Prurigo Nodularis

Cryosim-1 Safe, Effective in Patients With Prurigo Nodularis

A randomized, placebo-controlled trial of the selective transient receptor potential melastatin 8 agonist explored its efficacy and safety in PN.

FDA Accepts Galderma’s BLA for Nemolizumab for the Treatment of Prurigo Nodularis and Atopic Dermatitis

The FDA also granted nemolizumab Priority Review for prurigo nodularis.

Late-Breaking Data: Long-Term Safety and Efficacy of Largest Prurigo Nodularis Study Ever Conducted

Shawn Kwatra, MD, presented late-breaking data at AAD 2024 on the largest prurigo nodularis and nemolizumab clinical trial, OLYMPIA.

Late-Breaking Data: Povorcitinib Significantly Improves Itch and Lesions in Prurigo Nodularis

Shawn Kwatra, MD, shares positive updates on phase 2 oral povorcitinib for prurigo nodularis at AAD 2024.

Incyte and CMS Collaborate to Develop Povorcitinib in Numerous Chinese Regions

Povorcitinib is being evaluated for non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma, and chronic spontaneous urticaria.

Baldo Scassellati Sforzolini, MD, PhD, MBA: Expanding Nemolizumab’s Access

Scassellati Sforzolini discusses the significance of Galderma’s nemolizumab receiving 4 additional filing acceptances for prurigo nodularis and atopic dermatitis.

FDA Approves Nemolizumab for the Treatment of Prurigo Nodularis

Galderma’s nemolizumab is the first approved monoclonal antibody specifically inhibiting the signaling of IL-31.

Study Outlines Prurigo Nodularis and Psychiatric Comorbidities

The review found that patients with PN are approximately 1.3 times more susceptible to depression and 1.9 times more likely to experience anxiety.

Approximately 65% of Dermatologists in Japan Report Dissatisfaction With Treatment Options for Severe Prurigo Nodularis

Researchers conducted a web-based survey to gain insights into current clinical practice for PN in Japan.

Abrocitinib Shows Promise for Prurigo Nodularis

The JAK1 inhibitor provided significant relief for 2 patients with refractory PN.

Late-Breaking Data: 40-Week Efficacy and Safety of Oral Povorcitinib for Prurigo Nodularis

Shawn Kwatra, MD, presented the Incyte data at EADV 2024.

Clinical Features and Cytokine Pathways in Prurigo Nodularis vs Atopic Dermatitis

Jason Hawkes, MD, MS, emphasized the importance of biologic treatments transforming the management of both prurigo nodularis and atopic dermatitis.

Safe and Effective: Upadacitinib Shows Promise in PN Treatment

Significant reductions in itch scores and improved assessments of PN severity and quality of life were observed throughout the study.

Study Quantifies, Characterizes Health Care Burden of Prurigo Nodularis in England

The study represents the first to evaluate health care resource utilization among individuals with PN in England.

Available Therapeutics and Upcoming Advancements in Atopic Dermatitis and Prurigo Nodularis

Shawn Kwatra, MD, reviews key highlights of his sessions at Fall Clinical 2024 on the latest updates in itch conditions.

Nemolizumab Delivers Rapid Itch Response in Patients with PN

A post hoc analysis of OLYMPIA 1 and 2 trial data found significant improvement in the first 14 days of treatment.

Study Underscores High Economic and Comorbidity Burden for Patients with PN

These findings can help clinicians better treat the psychosocial factors associated with the disease.

NB-UVB Phototherapy Demonstrates Efficacy, Leads to Complete Response in Prurigo Nodularis

A study showed NB-UVB phototherapy effectively reduced prurigo nodularis symptoms, with 80% of patients achieving full response.

Dupilumab Reduces Lesion Burden in Patients with PN

Patients treated with dupilumab saw substantial healing, with over 70% achieving >50% lesion improvement in 24 weeks.

Nemolizumab Shows Significant Efficacy in Treating Signs, Symptoms of Prurigo Nodularis in OLYMPIA 1 Trial

Data from Galderma's OLYMPIA 1 trial was published in JAMA Dermatology.

Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.